03 June 2025
The fifteenth meeting of the Board of Directors of the Egyptian Drug Authority was held, chaired by Dr. Ali El-Ghamrawy, Chairman of the Authority, with the attendance of Prof. Dr. Khaled Abdel Ghaffar, Deputy Prime Minister for Human Development and Minister of Health and Population; Lieutenant General Kamel El-Wazir, Deputy Prime Minister for Industrial Development and Minister of Industry and Transport; Engineer Hassan Mohamed El-Khatib, Minister of Investment and Foreign Trade; Prof. Dr. Mohamed Awad Tag El-Din, Advisor to the President of the Republic for Health and Prevention Affairs; Prof. Dr. Adel Adawy, former Minister of Health and Population and Professor of Orthopedic Surgery; Dr. Hisham Stait, Chairman of the Egyptian Unified Procurement Authority for Medical Supply and Medical Technology Management; Prof. Dr. Ahmed Abdel Hamid Taha, Chairman of the General Authority for Healthcare Accreditation and Regulation; Prof. Dr. Amani Osama Kamel, Vice President of Ain Shams University for Graduate Studies and Research; and Engineer Hany Abdel Qader El-Desouky, Executive Director of the National Accreditation Council. Dr. Ali El-Ghamrawy prrsented the Authority’s vision for development and modernization and keeping up with global procedures applied in peer institutions internationally. The current status of the pharmaceutical market and the most important relevant performance indicators were also reviewed, where the total pharmaceutical market sales reached 309 billion EGP in 2024 compared to 216 billion EGP in 2023, representing a 43% growth in financial value. The meeting included a presentation of the latest developments of the Permanent Committee for the Egyptian Pharmacopeia, in addition to reviewing the most prominent achievements related to the digitalization of procedures within the Authority, contributing to raising the efficiency of the services provided and supporting the institutional work environment. It also included a presentation of the latest updates on international accreditations and participations of the Egyptian Drug Authority, as the Authority obtained several international accreditations in the recent period. Most notably, the Authority was accredited in the field of medicine and obtained Maturity Level 3 in the field of medicines from the World Health Organization in December 2024, after having obtained Maturity Level 3 in the field of vaccines in March 2022. The Authority’s laboratories were also accredited by the World Health Organization and the European Union, which represents an important step toward considering the Authority’s laboratories as internationally recognized reference laboratories relied upon for analysis at the international level. Also presented were the Authority’s contributions to international training programs, where it supports African and Arab countries in building their regulatory systems (Regulatory System Strengthening). The Egyptian Drug Authority’s obtaining of Maturity Level 3 from the WHO in the fields of medicines and vaccines had a significant impact on this role, placing a great responsibility on the Authority to support African countries in this field. The Authority was also selected as a regional training center by AUDA-NEPAD, making the Authority’s Continuing Professional Development Center a regional center of regulatory excellence in Africa (RCORE). Extending this pivotal role, 12 international training programs were delivered to various Arab and African countries such as Libya, Yemen, Ghana, and Algeria. During the meeting, the latest developments in internship training were also reviewed, including the pilot launch of the new Learning Management System (LMS) platform. Attending the meeting from the Authority's side were Dr. Tamer El-Hossieny, Vice Chairman of the Egyptian Drug Authority; Prof. Dr. Mohamed El-Demerdash, Deputy President of the State Council and Legal Advisor to the Authority; Prof. Dr. Ahmed Abu Taleb, Financial Advisor to the Authority; Dr. Rasha Ziada, Assistant Chairman of the Authority Technical Development and Building Capacity Affairs and Board Member of the Authority; Dr. Amany Gawdet, Associate to the Chairman of the Authority for the President's Office Affairs and Supervisor of the Central Administration for the Chairman’s Office; Dr. Amira Mahgoub, Head of the Central Administration for Operations; Dr. Osama Hatem, Associate to the Chairman of the Authority for Policy and International Cooperation Affairs and Supervisor of the Central Administration for Pharmaceutical Policies and Market Access; Dr. Dalia Abu Hussein, General Manager of the Quality Assurance. #Egyptian_Drug_Authority #Media_Center_of_the_Egyptian_Drug_Authority #Egyptian_Medicine |